[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"subjective-cognitive-decline\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:subjective-cognitive-decline":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,18,0,[8,59,85,112,140,162,184,218,244,264,286,317,335,364,386,415,440,465],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":31,"overallStatus":46,"whyStopped":4,"lastUpdateSubmitDate":47,"lastUpdatePostDateStruct":48,"startDateStruct":51,"completionDateStruct":53,"leadSponsor":55,"locationsCount":58},"100642364","using-artificial-intelligence-to-detect-early-signs-of-alzheimers-disease-in-people-with-memory-concerns-100642364",false,"NCT07652931","Using Artificial Intelligence to Detect Early Signs of Alzheimer's Disease in People With Memory Concerns","AHEAD: AI-driven Brain Health for Early Alzheimer's Disease Detection in Individuals With Subjective Cognitive Decline","AHEAD","Inclusion Criteria:\n\n1. Diagnosis of Subjective Cognitive Decline (SCD) according to international diagnostic criteria (Jessen et al., 2014).\n2. Self-experienced persistent decline in cognitive capacity in comparison with a previously normal status and unrelated to an acute event.\n3. Normal age-, gender-, and education-adjusted performance on standardized cognitive tests used to classify mild cognitive impairment (MCI) or prodromal AD.\n4. Age greater than or equal to 40 years.\n5. Native Italian Speaker.\n6. Stable pharmacological treatment for at least 4 weeks prior to enrollment.\n7. Provision of oral and written informed consent to study participation.\n\nExclusion Criteria:\n\n1. Presence of MCI, prodromal AD, or dementia.\n2. Any major systemic, psychiatric, or neurological disturbance.\n3. Medical conditions or substance abuse that could interfere with cognition.\n4. Pacemaker and\u002For other implanted neurostimulation devices in the head\u002Fneck district.\n5. Contraindications to undergoing MRI examination.\n6. Brain damage at routine MRI, including extensive cerebrovascular disorders.\n7. Traumatic or surgical wounds that could determine a risk of infection at the site of non-invasive stimulation.\n8. Scalp alterations that could determine the spread of excessive current from the device.\n9. Known history of epilepsy (due to small risk of seizure induction from rTMS in epileptic patients).\n10. Denial of oral and written informed consent to study participation.","ALL","40 Years",{"count":20,"type":21},300,"ESTIMATED","INTERVENTIONAL",[24],"NA","AHEAD is a prospective, longitudinal, risk-stratified single-arm interventional study enrolling 300 patients with Subjective Cognitive Decline (SCD) at IRCCS San Raffaele Hospital, Milan, Italy.\n\nThe study uses artificial intelligence (AI) to integrate multimodal data - including MRI, EEG, Optical Coherence Tomography (OCT), neuropsychological assessments, and plasma biomarkers - to identify individuals with underlying Alzheimer's disease (AD) biology and predict cognitive progression.\n\nOnly participants found to be AD plasma biomarker positive (SCD+) undergo longitudinal follow-up at 12 and 24 months. Participants classified as high risk additionally receive a 6-month personalized multidisciplinary intervention combining high-frequency transcranial magnetic stimulation (TMS), digital cognitive training, structured physical exercise, and targeted management of modifiable vascular and behavioral risk factors.",[27,28,29,30],"Subjective Cognitive Decline","Alzheimer Disease","Mild Cognitive Impairment","Cognitive Decline",[27,32,33,34,35,36,37,38,39,40,41,42,43,44,45],"Alzheimer's disease","Artificial Intelligence","Transcranial Magnetic Stimulation","Plasma biomarkers","p-tau217","MRI","EEG","Optical Coherence Tomography","Cognitive Training","Physical Exercise","Brain Health","APOE","Machine Learning","Deep Learning","NOT_YET_RECRUITING","2026-06-11",{"date":49,"type":50},"2026-06-17","ACTUAL",{"date":52,"type":21},"2026-08-01",{"date":54,"type":21},"2029-08-01",{"name":56,"class":57},"IRCCS San Raffaele","OTHER",1,{"id":60,"slug":61,"hasResults":11,"nctId":62,"briefTitle":63,"officialTitle":64,"acronym":65,"eligibilityCriteria":66,"healthyVolunteers":67,"sex":17,"minAge":68,"maxAge":4,"enrollmentInfo":69,"targetDuration":4,"studyType":22,"phases":71,"briefSummary":73,"conditions":74,"keywords":4,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":77,"startDateStruct":79,"completionDateStruct":81,"leadSponsor":83,"locationsCount":58},"100516281","early-phase-1-attentional-mechanisms-in-scd-100516281","NCT06002477","Attentional Mechanisms in SCD","Attentional Mechanisms of Cognitive Compensation in Subjective Cognitive Decline","AMoCC-SCD","Inclusion Criteria:\n\n1. age ≥ 55\n2. Montreal Cognitive Assessment (MoCA) \\> 25 AND Global Deterioration Scale (GDS) rating \\\u003C 3\n3. Non-smokers\n\nExclusion Criteria:\n\n1. medical contraindications to the drug challenge\n2. primary neurological disorder (such as stroke, epilepsy, etc.)",true,"55 Years",{"count":70,"type":21},80,[72],"EARLY_PHASE1","This study will use an anticholinergic pharmacological probe to examine attention network function in SCD using EEG. The overall hypothesis is that in older adults with SCD, normal cognitive performance is maintained by compensatory attention network activity, supported by enhanced cholinergic function. The investigators anticipate that SCD will be associated with greater compensatory attention network activity and that disrupting this compensatory process through anticholinergic challenge will result in a greater negative effect on attentional performance (Attention Network Test, ANT) and attention network functioning (EEG) in older adults with greater subjective cognitive concern.",[27],"RECRUITING","2026-06-02",{"date":78,"type":50},"2026-06-04",{"date":80,"type":50},"2025-06-06",{"date":82,"type":21},"2028-06-30",{"name":84,"class":57},"Vanderbilt University Medical Center",{"id":86,"slug":87,"hasResults":11,"nctId":88,"briefTitle":89,"officialTitle":89,"acronym":4,"eligibilityCriteria":90,"healthyVolunteers":67,"sex":17,"minAge":91,"maxAge":4,"enrollmentInfo":92,"targetDuration":4,"studyType":22,"phases":94,"briefSummary":95,"conditions":96,"keywords":98,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":103,"lastUpdatePostDateStruct":104,"startDateStruct":106,"completionDateStruct":108,"leadSponsor":110,"locationsCount":58},"100632252","prediction-of-cognitive-test-performance-using-ai-based-analysis-of-narrative-speech-100632252","NCT07511270","Prediction of Cognitive Test Performance Using AI-Based Analysis of Narrative Speech","Inclusion Criteria:\n\n1. Age 50 years or older\n2. Able to communicate verbally and understand study instructions\n3. Able to hear and speak clearly\n4. Willing and able to provide written informed consent\n\nExclusion Criteria:\n\n1. Severe speech or hearing impairment\n2. History of major psychiatric disorders\n3. History of stroke, traumatic brain injury, Parkinson's disease, epilepsy, or other neurodegenerative diseases\n4. Current use of medications that may affect cognitive performance\n5. Unable to complete the study procedures due to severe attention deficits or agitation","50 Years",{"count":93,"type":21},150,[24],"This study aims to evaluate a new artificial intelligence (AI)-based method for measuring cognitive function using speech recordings. Participants will complete a short storytelling task in which they describe a story based on an image while their voice is recorded using a computer or mobile device.\n\nThe speech recordings will be analyzed using AI technology to identify patterns in speech that may be related to cognitive function. The system will then estimate scores that correspond to commonly used cognitive tests.\n\nTo evaluate the accuracy of this method, the AI-generated scores will be compared with results from standard cognitive assessments administered by trained researchers. These assessments may include tests commonly used to measure memory, attention, and other cognitive abilities.\n\nThe goal of this study is to determine whether speech analysis using AI can provide a convenient and efficient approach for cognitive assessment. If successful, this technology may help support early detection of cognitive decline and provide a practical tool for large-scale or remote cognitive screening.",[97,29,27],"Cognitive Function Assessment",[33,99,100,101,102,29],"Speech Biomarkers","Storytelling Task","Cognitive Screening","Voice Analysis","2026-03-30",{"date":105,"type":50},"2026-04-06",{"date":107,"type":50},"2025-12-01",{"date":109,"type":21},"2026-04-30",{"name":111,"class":57},"Chang Gung Memorial Hospital",{"id":113,"slug":114,"hasResults":11,"nctId":115,"briefTitle":116,"officialTitle":117,"acronym":4,"eligibilityCriteria":118,"healthyVolunteers":11,"sex":17,"minAge":119,"maxAge":4,"enrollmentInfo":120,"targetDuration":4,"studyType":22,"phases":122,"briefSummary":123,"conditions":124,"keywords":126,"overallStatus":46,"whyStopped":4,"lastUpdateSubmitDate":132,"lastUpdatePostDateStruct":133,"startDateStruct":135,"completionDateStruct":136,"leadSponsor":138,"locationsCount":58},"100628573","chinese-classics-recitation-training-in-subjective-cognitive-decline-100628573","NCT07463391","Chinese Classics Recitation Training in Subjective Cognitive Decline","The Effect of Memory Training by Chinese Classics Recitation on Individuals With Subjective Cognitive Decline","Inclusion Criteria:\n\n* Age ≥ 60 years old\n* At least two \"yes\" responses to the following questions are required:\n\n  1. Forgetting where things are placed?\n  2. Unable to recall the names of good friends?\n  3. Unable to follow and recall conversation?\n  4. Subjective memory problems?\n  5. Consider own memory to be worse than others of a similar age?\n\nExclusion Criteria:\n\n* Objective cognitive impairment defined as ≥ 1.5 standard deviations below standardized cognitive testing (e.g., MMSE)\n* Diagnosis of MCI\n* Clinical Dementia Rating (CDR) ≥ 0.5\n* Diagnosis of major depressive disorder\n* Beck Anxiety Inventory score ≥ 16\n* Other medical or neurological conditions that could explain cognitive decline (e.g., vascular dementia, traumatic brain injury)\n* Claustrophobia\n* Contraindications of MRI (e.g., non-MRI-compatible cardiac pacemaker or devices implanted within the past three months)","60 Years",{"count":121,"type":21},60,[24],"Subjective cognitive decline (SCD) is considered a preclinical condition associated with an increased risk of dementia and Alzheimer's disease. Effective early behavioral interventions remain limited, and the neurobiological mechanisms underlying cognitive training effects are not fully understood, particularly in culturally specific educational contexts.\n\nThis randomized, assessor-blinded, controlled clinical trial will enroll 60 individuals with SCD to evaluate the effects of a six-month structured Chinese Classics recitation training program. Participants will be randomly assigned to either an intervention group or a non-active control group. Assessments will be conducted at baseline, immediately post-intervention, and during annual follow-up.\n\nMultimodal evaluations will include neuropsychological testing, functional magnetic resonance imaging (fMRI), electroencephalography (EEG), blood biomarker profiling, gut microbiota analysis, and fecal metabolomics. The study aims to examine clinical outcomes and explore potential neurobiological and systemic correlates associated with culturally adapted cognitive training.",[125,27],"Subjective Cognitive Decline (SCD)",[127,128,129,130,131],"subjective cognitive decline","memory training","Chinese Classics","recitation","randomized controlled trial","2026-03-05",{"date":134,"type":50},"2026-03-11",{"date":52,"type":21},{"date":137,"type":21},"2032-12-31",{"name":139,"class":57},"China Medical University Hospital",{"id":141,"slug":142,"hasResults":11,"nctId":143,"briefTitle":144,"officialTitle":145,"acronym":4,"eligibilityCriteria":146,"healthyVolunteers":11,"sex":17,"minAge":91,"maxAge":4,"enrollmentInfo":147,"targetDuration":149,"studyType":150,"phases":4,"briefSummary":151,"conditions":152,"keywords":4,"overallStatus":46,"whyStopped":4,"lastUpdateSubmitDate":153,"lastUpdatePostDateStruct":154,"startDateStruct":156,"completionDateStruct":158,"leadSponsor":160,"locationsCount":58},"100557772","under-represented-communities-diagnosed-with-scd-or-mci-through-tele-cog-100557772","NCT06542458","Under-Represented Communities Diagnosed With SCD or MCI Through Tele-Cog","A Cohort Study of Older Adults From Under-resourced\u002FUnder-represented Communities Diagnosed With Subjective Cognitive Decline (SCD) or Mild Cognitive Disorder (MCI) Through Standard of Care Tele-Cog Visits (Tele-Cog)","Inclusion Criteria:\n\n1. Adults ages 50 years and older\n2. Diagnosed with subjective cognitive concerns (SCD) or objective cognitive decline with mostly intact functioning (MCI diagnosis) as part of clinical work up\n3. Fluent in English\n4. Able to provide voluntary informed consent\n5. Willing and able to undergo all study procedures\n6. Able to delegate, if possible, a study partner to contribute information regarding daily activities and cognition\n\nExclusion Criteria:\n\n1. Diagnosis of dementia at baseline.\n2. Inability to give informed consent.\n3. High risk of adverse emotional or behavioral reaction based on investigator's clinical evaluation (e.g., evidence of serious personality disorder, antisocial behavior, serious current stressors, lack of meaningful social support).",{"count":148,"type":21},1000,"5 Years","OBSERVATIONAL","Overall, this study's primary aim is to establish a prospective, longitudinal, observational cohort study of older adults at risk for dementia from under-resourced\u002Funderrepresented communities. More specifically, older adults diagnosed with subjective cognitive decline (SCD) or Mild Cognitive Impairment (MCI) during clinical care offered via the Tele-Cog clinic would be recruited for more comprehensive data collection to characterize the clinical presentation and course of illness over multiple timepoints spread out longitudinally.",[29,27],"2026-02-23",{"date":155,"type":50},"2026-02-25",{"date":157,"type":21},"2026-12-01",{"date":159,"type":21},"2032-01-01",{"name":161,"class":57},"Ohio State University",{"id":163,"slug":164,"hasResults":11,"nctId":165,"briefTitle":166,"officialTitle":167,"acronym":4,"eligibilityCriteria":168,"healthyVolunteers":11,"sex":17,"minAge":68,"maxAge":169,"enrollmentInfo":170,"targetDuration":4,"studyType":22,"phases":172,"briefSummary":173,"conditions":174,"keywords":4,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":175,"lastUpdatePostDateStruct":176,"startDateStruct":178,"completionDateStruct":180,"leadSponsor":182,"locationsCount":58},"100523390","dtms-for-subjective-cognitive-decline-100523390","NCT06095063","dTMS for Subjective Cognitive Decline","Effect of Deep Transcranial Magnetic Stimulation (dTMS) on Cognition in Older Adults With Subjective Cognitive Decline (SCD)","Inclusion Criteria:\n\n* have a family history of late onset sporadic Alzheimer's disease (AD) as defined by having a first degree relative, living or deceased, with a probable or confirmed diagnosis of AD\n* have subjective memory decline and concern about memory changes\n* score 26 or higher on the Montreal Cognitive Assessment (MoCA)\n* are willing to provide informed consent\n* are able to follow the treatment schedule\n* are stable on medications for 2 months and are not expected to change medication during the entire study period (if they are taking medications)\n* have a satisfactory safety screening questionnaire for TMS\n* have an informant\u002Fstudy partner who is able to complete study questionnaires regarding the participant\n\nExclusion Criteria:\n\n* have a metal plate in their head, except in the mouth (such as an ear implant, implanted brain stimulators, aneurysm clips)\n* have known increased pressure or a history of increased pressure in their brain, which may increase their risk for having seizures\n* have a cardiac pacemaker\n* have an implanted medication pump\n* have a central venous line\n* have a significant heart condition\n* have current depression or a history of any psychotic disorder, bipolar disorder, eating disorder, obsessive compulsive disorder, post-traumatic stress disorder, or dementia other than AD\n* have a history of substance abuse in the last 6 months\n* have a history of stroke or other brain lesions\n* have a personal history of epilepsy\n* have a family history of epilepsy\n* are a pregnant or breast-feeding woman\n* have a history of abnormal MRI of the brain\n* have significant hearing loss requiring use of hearing aids\n* have untreated hypo- or hyper-thyroidism\n* have TMS contraindications\n* have unstable medical condition(s)\n* regularly use benzodiazepines or other hypnotics within 2 weeks of randomization","70 Years",{"count":171,"type":21},30,[24],"Deep transcranial magnetic stimulation (dTMS) is a brain stimulation technique that involves generating a brief magnetic field in a coil that is placed on the scalp. The magnetic field passes through the skull and induces a weak electrical current in the brain that briefly activates neural circuits at the stimulation site. The Brainsway dTMS H7-Coil is able to target an area of the brain that has been shown in studies to be linked to greater resilience to cognitive decline. In this study, the investigators will combine dTMS with cognitive training in older adults with subjective cognitive decline (SCD) and examine the effect of this treatment on memory, other cognitive abilities, and mood. In addition, the investigators will examine the combined effects of dTMS and cognitive training on brain activity as measured using electroencephalography (EEG).\n\nApproximately 30 older adults from ages 55 to 70 with SCD and a positive family history of Alzheimer's disease will be enrolled in this study.",[28,27],"2025-10-23",{"date":177,"type":50},"2025-10-27",{"date":179,"type":50},"2023-11-15",{"date":181,"type":21},"2026-11-15",{"name":183,"class":57},"Rotman Research Institute at Baycrest",{"id":185,"slug":186,"hasResults":11,"nctId":187,"briefTitle":188,"officialTitle":189,"acronym":190,"eligibilityCriteria":191,"healthyVolunteers":11,"sex":17,"minAge":119,"maxAge":192,"enrollmentInfo":193,"targetDuration":4,"studyType":22,"phases":195,"briefSummary":197,"conditions":198,"keywords":202,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":209,"lastUpdatePostDateStruct":210,"startDateStruct":212,"completionDateStruct":214,"leadSponsor":216,"locationsCount":58},"100464703","phase-2-impact-of-intensive-treatment-of-sbp-on-brain-perfusion-amyloid-and-tau-ipat-study-100464703","NCT05331144","Impact of Intensive Treatment of SBP on Brain Perfusion, Amyloid, and Tau (IPAT Study)","Impact of Intensive Treatment of Systolic Blood Pressure on Brain Perfusion, Amyloid, and Tau in Older Adults (IPAT Study)","IPAT","Inclusion Criteria:\n\n* Age 60-85, all races\u002Fethnicities, and both sexes are eligible;\n* Mini-Mental State Exam (MMSE) ≥ 26 to exclude gross dementia; based on clinical judgment, may be rescreened in ≥ 7 days;\n* Individuals with SBP ≥ 130 and SBP ≤ 180 if on 0 or 1 antihypertensive medications; ≥130 and ≤170 on up to 2 medications; ≥130 and ≤160 on up to 3 medications; ≥130 and ≤150 on up to 4 medications. Those on antihypertensives are eligible. If an individual, not treated for hypertension (HTN), has a SBP ≥ 125 mmHg, consider rescreening after 24 hours;\n* Willingness to be randomized into the treatment groups and ability to return to clinic for follow-up visits over 24 months;\n* Fluency in English or Spanish or both, adequate visual and auditory acuity to allow neuropsychological testing;\n* Participants must have a regular healthcare provider.\n\nExclusion Criteria:\n\n* Clinically documented history of stroke, focal neurological signs or other major cerebrovascular diseases based on clinical judgment or MRI\u002FCT scans such as evidence of infection, infarction, or other brain lesions;\n* Diagnosis of AD or other type of dementia, or significant neurologic diseases such as Parkinson's disease, seizure disorder, multiple sclerosis, history of severe head trauma or normal pressure hydrocephalus;\n* Evidence of severe major depression (GDS ≥ 12, may be rescreened after 12 weeks or longer if evidence of reactive depression or temporary mood disturbances) or clinically significant psychopathology, (e.g., psychosis and schizophrenia); if hospitalized in past year, can be rescreened in 6 months; or presence of a major psychiatric disorder that in the investigator's opinion, could interfere with adherence to research assessments or procedures.\n* Unstable heart disease based on clinical judgment (e.g., heart attack\u002Fcardiac arrest, cardiac bypass procedures within previous 6 months and congestive heart failure), or other severe medical conditions;\n* History of atrial fibrillation and evidence on ECG with any of the following: active symptoms of persistent palpitation, dizziness, history of syncope, chest pain, dyspnea, orthopnea, shortness of breath at rest, or paroxysmal nocturnal dyspnea within the past 6 months; resting heart rate of \\\u003C 30 or \\> 110 bpm; taking class I or III antiarrhythmic drugs including flecainide, propafenone, dronedarone, sotalol, dofetilide, and amiodarone; or clinical concerns for safely participating in lowering blood pressure.\n* Systolic BP equal or greater than 180 mmHg and\u002For diastolic BP equal or greater than 110 mmHg, may be rescreened in 1 week.\n* Orthostatic hypotension, defined as the third standing SBP \\\u003C 100mmHg, may be rescreened after 2 weeks;\n* History of significant autoimmune disorders such as systemic lupus erythematosus, rheumatoid arthritis or polymyalgia rheumatica;\n* Significant history of alcoholism or drug abuse within the last five years;\n* Uncontrolled diabetes mellitus, defined as hemoglobin A1C \\> 7.5%, or requiring insulin treatment;\n* Regularly smoking cigarettes within the past year;\n* Pacemaker or other medical device of metal that precludes performing MRI;\n* Women with a potential for pregnancy, lactation\u002Fchildbearing (2 year post-menopausal or surgically sterile to be considered not childbearing potential);\n* Participant enrolled in another investigational drug or device study, either currently or within the past 2 months;\n* Severe obesity with BMI \\> 40 ; clinical judgment should be applied in all cases to assess patient safety and anticipated compliance;\n* Allergy to angiotensin receptor blockers (ARBs), i.e., drugs that have a suffix \"-sartan\"; allergy to amlodipine;\n* Abnormal screening laboratory tests (e.g., liver ALT and AST \\> 3 x ULN, GFR \\\u003C 30 or Hct \\\u003C 28%); may be rescreened after 2 weeks or longer;\n* A medical condition likely to limit survival to less than 3 years;\n* Participant has any condition(s) judged by the study investigator to be medically inappropriate, risky or likely to cause poor study compliance. For example:\n\n  1. Plans to move outside the clinic catchment area in the next 2 years;\n  2. Significant concerns about participation in the study from spouse, significant other, or family members;\n  3. Lack of support from primary health care provider;\n  4. Residence too far from the study clinic site such that transportation is a barrier including persons who require transportation assistance provided by the study clinic funds for screening or randomization visits;\n  5. Residence in a nursing home; persons residing in an assisted living or retirement community are eligible if they meet the other criteria;\n  6. Other medical, psychiatric, or behavioral factors that, in the judgment of the site PI or clinician, may interfere with study participation or the ability to follow the study Protocol.\n  7. Couples or significant partners who live together cannot be enrolled or participate simultaneously in the study.","85 Years",{"count":194,"type":21},180,[196],"PHASE2","The purpose of this study is to determine if intensive lowering of systolic blood pressure (SBP), using FDA approved medications (antihypertensive), reduces Alzheimer's Disease pathology (i.e., excessive brain amyloid and tau protein deposition) in older adults at high risk for memory decline or dementia.",[199,200,27,201],"Cognitively Normal Older Adults","Hypertension","Family History of Dementia",[203,204,205,206,207,208],"Dementia","Alzheimer's Disease","Cognitive Function","Blood Pressure","Amyloid","Tau","2025-07-31",{"date":211,"type":50},"2025-08-05",{"date":213,"type":50},"2022-10-25",{"date":215,"type":21},"2027-12-31",{"name":217,"class":57},"Rong Zhang",{"id":219,"slug":220,"hasResults":11,"nctId":221,"briefTitle":222,"officialTitle":223,"acronym":4,"eligibilityCriteria":224,"healthyVolunteers":11,"sex":17,"minAge":91,"maxAge":119,"enrollmentInfo":225,"targetDuration":4,"studyType":22,"phases":226,"briefSummary":227,"conditions":228,"keywords":229,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":235,"lastUpdatePostDateStruct":236,"startDateStruct":238,"completionDateStruct":240,"leadSponsor":242,"locationsCount":58},"100599528","exergame-assisted-simultaneous-motor-cognitive-training-for-middle-aged-old-adults-in-china-100599528","NCT07085663","Exergame-assisted Simultaneous Motor-cognitive Training for Middle-aged Old Adults in China","Exergame-assisted Simultaneous Motor-cognitive Training for Middle-aged Old Adults in China: a Feasibility and Pilot Randomized Controlled Trail Study","Inclusion Criteria:\n\n* people between 50 and 60 years of age\n* living in mainland China\n* confirmed subjective cognitive decline with the following diagnostic criteria; a confirmed case of subjective cognitive decline that meets the subjective cognitive decline-9 scale and an exclusion of mild cognitive impairment cases using the Montreal Cognitive Assessment scale to rule out mild cognitive impairment; subjective decline in memory rather than other cognitive domains; episodes of subjective cognitive decline within the past 5 years; participants perceived to experience a sustained decline in cognitive performance compared to previous normality, independent of an acute event.\n* the absence of a medical condition that renders exercise inappropriate. This includes, but is not limited to, heart disease, hypertension, diabetes, respiratory disease (e.g., chronic obstructive pulmonary disease), joint and bone disease, and neurological disease (e.g., parkinson's disease)\n* have the ability to perform independent activities of daily living (as measured by the independent activities of daily living scale)\n* have no history of falls\n* have no language barriers and have adequate communication skills\n\nExclusion Criteria:\n\n* active mental disorder, serious mental illness, neurological disorder, or cognitive impairment (standard mild cognitive impairment, prodromal Alzheimer's disease or dementia, or other significant cognitive deficits)\n* substance use for a long-term mental or neurological illness\n* severe mobility or sensory impairments that may prevent participation in research activities\n* unstable or acute medical conditions\n* individuals who have recently undergone major surgery or have acute orthopedic conditions\n* individuals who refuse to participate",{"count":171,"type":21},[24],"To develop and conduct a pilot trial on the effectiveness of a technology-based (exergame) intervention approach for the middle-aged old adults' population in China. The study will examine the feasibility of the intervention and estimate its preliminary effects in improving their physical, cognitive, and dual-task performance.",[27],[230,127,231,232,233,234],"exergame","middle-aged","physical performance","cognitive performance","dual-task performance","2025-07-24",{"date":237,"type":50},"2025-07-25",{"date":239,"type":50},"2025-05-20",{"date":241,"type":21},"2025-08-30",{"name":243,"class":57},"The Hong Kong Polytechnic University",{"id":245,"slug":246,"hasResults":11,"nctId":247,"briefTitle":248,"officialTitle":249,"acronym":4,"eligibilityCriteria":250,"healthyVolunteers":67,"sex":17,"minAge":251,"maxAge":4,"enrollmentInfo":252,"targetDuration":4,"studyType":150,"phases":4,"briefSummary":254,"conditions":255,"keywords":4,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":256,"lastUpdatePostDateStruct":257,"startDateStruct":259,"completionDateStruct":261,"leadSponsor":262,"locationsCount":58},"100351108","longitudinal-study-for-the-characterization-of-the-phases-of-subjective-perception-of-cognitive-decline-and-mild-cognitive-impairment-of-alzheimers-disease-100351108","NCT03851523","Longitudinal Study for the Characterization of the Phases of Subjective Perception of Cognitive Decline and Mild Cognitive Impairment of Alzheimer's Disease.","AlfaCognition: Longitudinal Study for the Characterization of the Phases of Subjective Perception of Cognitive Decline and Mild Cognitive Impairment of Alzheimer's Disease.","Inclusion Criteria:\n\n1. Men and women between 45 and 74 years at the time of inclusion in the 45-65\u002FFPM2012 study or older than 45 for persons who have not previously participated in 45-65\u002FFPM2012.\n2. Cognitively healthy persons with SCD, as well as people with MCI and mild dementia.\n3. Participation of a relative to perform the subjective memory complaint and clinical interview.\n\nExclusion criteria:\n\n1. Any significant systemic illness or unstable medical condition which could lead to difficulty complying with the protocol.\n2. Any significant disorder that could course with cognitive impairment that is not related to AD.\n3. Family history of monogenic AD.","45 Years",{"count":253,"type":21},400,"Alzheimer's disease (AD) is the leading cause of dementia and its prevalence is estimated to exceed 100 million affects by 2050, becoming the main public health problem worldwide. AD is considered a clinicopathological entity characterized by a progressive cognitive impairment with affectation of memory and other cognitive domains, which underlies a neuropathological pattern with extracellular accumulation of β-amyloid protein (Aβ) in the form of neuritic plaques, intracellular deposits of tau protein in the form of neuritic strands and neurofibrillary tangles, neuronal and synaptic loss and glial proliferation. Classically, its definitive diagnosis implied the existence of a clinical phenotype compatible with dementia, together with the neuropathological findings characteristic of the disease. More recently, evidence of clinical and biological changes leading to the dementia phase has led to the development of new diagnostic criteria that divide the course of AD into 3 stages: (1) a pre-clinical phase, which would include persons with positive biomarkers with normal cognitive performance for their age and educational level; (2) a phase of mild cognitive impairment (MCI), characterized by cognitive performance lower than expected by age and educational level; and (3) a dementia phase, once cognitive deficits interfere with the activities of daily living.\n\nRecent research has also shed light into the subdivision of each of the above-mentioned stages in distinct phases. For example, the existence of a subjective perception of cognitive decline or a subtle cognitive decline, have been postulated as phases within the AD preclinical stage.\n\nThe lack of positive results in the different clinical trials performed to date in patients with AD dementia has redirected the focus of therapeutic strategies towards preventing the development of dementia. For this reason, a detailed characterization of the successive clinical and biological changes that lead to the dementia stage is of vital importance in identifying the persons who could benefit from a possible preventive strategy, as well as the optimal moment to carry out the intervention. The the scientific community, is convinced that intervention aiming to prevent the clinical development of AD dementia must be implemented several years before the first symptoms arise.\n\nIn this context, the present project is developed under the hypothesis that subjective cognitive decline (SCD) in individuals with a performance in cognitive tests within normality represents the first symptomatic manifestation of AD. In persons with SCD, the presence of a higher intensity of subjective complaint quantified using a specific subjective complaint questionnaire (SCD-Q) will be associated with lower cognitive performance and a higher rate of conversion to MCI and\u002For dementia. The relationship between the perception of cognitive decline by the subject and his\u002Fher relative will differently vary depending on the stage of the disease: in subjects with progressive cognitive impairment, the subjective perception of cognitive decline will decrease with disease progression whereas the perception of decline will increase with disease progression in their relatives. The degree of perception of cognitive decline throughout the different phases of the disease will be correlated with cognitive and affective patterns as well as with changes in AD biomarkers. These changes will be related to specific brain patterns and abnormal levels of AD biomarkers, which on the other hand will also be present in patients with MCI and mild dementia due to AD.\n\nThe present study has two main objectives that are:\n\n1. To characterize from a cognitive and biomarker (when available) point of view persons with SCD and to study its association with the risk of presenting a progressive cognitive deterioration.\n2. To study the evolution of the subjective perception of cognitive impairment by the participants and their relatives and to analyze its impact in cognitive, affective and functional terms along the clinical-biological continuum of AD.",[28,29,27],"2025-05-27",{"date":258,"type":50},"2025-05-31",{"date":260,"type":50},"2018-02-12",{"date":215,"type":21},{"name":263,"class":57},"Barcelonabeta Brain Research Center, Pasqual Maragall Foundation",{"id":265,"slug":266,"hasResults":11,"nctId":267,"briefTitle":268,"officialTitle":269,"acronym":4,"eligibilityCriteria":270,"healthyVolunteers":67,"sex":17,"minAge":91,"maxAge":4,"enrollmentInfo":271,"targetDuration":4,"studyType":22,"phases":272,"briefSummary":273,"conditions":274,"keywords":275,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":277,"lastUpdatePostDateStruct":278,"startDateStruct":280,"completionDateStruct":282,"leadSponsor":284,"locationsCount":58},"100570800","german-validation-study-of-the-subjective-cognitive-decline-questionnaire-scd-q-100570800","NCT06711952","German Validation Study of the Subjective Cognitive Decline Questionnaire (SCD-Q)","German Validation Study of the Subjective Cognitive Decline Questionnaire (SCD-Q) and Its Potential Use in Large Cohorts","Inclusion Criteria:\n\n* Medical appointment for dementia diagnostics at the Alzheimer Therapie- und Forschungszentrum\n* Provision of signed, written and dated informed consent\n* Capacity to give informed consent\n\nExclusion Criteria:\n\n* dementia in a very advance stage\n* Illiteracy",{"count":20,"type":21},[24],"The SCD-Q (Subjective Cognitive Decline-Questionnaire) is an established instrument to quantify self-perceived cognitive decline. Both self- and informant-rated versions of the SCD-Q are available. However, the SCD-Q has not been validated in the German language yet. Hence, the investigators aim to validate the self-reported SCD-Q in a clinical sample in Germany.",[28,27],[204,27,276],"German Validation","2025-05-22",{"date":279,"type":50},"2025-05-29",{"date":281,"type":50},"2023-02-01",{"date":283,"type":21},"2025-08-31",{"name":285,"class":57},"Ludwig-Maximilians - University of Munich",{"id":287,"slug":288,"hasResults":11,"nctId":289,"briefTitle":290,"officialTitle":291,"acronym":292,"eligibilityCriteria":293,"healthyVolunteers":67,"sex":17,"minAge":119,"maxAge":4,"enrollmentInfo":294,"targetDuration":296,"studyType":150,"phases":4,"briefSummary":297,"conditions":298,"keywords":302,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":307,"lastUpdatePostDateStruct":308,"startDateStruct":310,"completionDateStruct":312,"leadSponsor":314,"locationsCount":58},"100592421","home-based-brain-monitoring-with-a-garment-eeg-to-study-cognitive-decline-in-the-aging-population-100592421","NCT06993207","HOme-based Brain Monitoring With a GARment-EEG to Study Cognitive Decline in the Aging Population","Validation of a Home-use Instrument for the Quantification of Cognitive Function in a Population at Risk of Dementia","Hogar","General Inclusion Criteria:\n\n* Native Spanish speaker.\n* Agree to the examination procedures and tests.\n* Ability to involve a close family member or friend for functional evaluation.\n* Normal or corrected-to-normal color vision.\n* No medical condition requiring chronic systemic medication with psychoactive effects causing confusion.\n* No severe psychiatric (according to DSM-V) or neurological diseases (epilepsy with frequent seizures (\\>1\u002Fmonth) in the last year, multiple sclerosis, etc.).\n* No diseases that may interfere with cognitive functions (renal insufficiency on hemodialysis, liver cirrhosis, chronic pulmonary disease with oxygen therapy, solid organ transplant, fibromyalgia, active cancer under treatment).\n* No severe hearing and\u002For visual impairments, neurodevelopmental, or psychomotor disorders.\n* No brain injuries that may interfere with cognitive functions (history of traumatic brain injury with parenchymal injury or macroscopic ischemic stroke of large extra-axial vessels or hemorrhagic stroke, brain surgery, brain tumors, or other causes that could result in acquired brain damage such as brain chemotherapy or radiotherapy).\n* No treatment with antipsychotic agents in the 6 months prior to the initial assessment.\n* No medical condition requiring chronic systemic medication with psychoactive effects causing confusion. No psychiatric or neurological medication.\n* No alcohol or drug abuse.\n* No serious health problems in the last 12 months (especially neurological or cardiac disorders).\n\nInclusion Criteria 'Mild Dementia' group:\n\n* Diagnosis of Alzheimer's type dementia, based on a clinical and cognitive assessment conducted by a physician.\n* Diagnosis of vascular or mixed type dementia, based on a clinical and cognitive assessment conducted by a physician.\n* Lack of autonomy in: 1. basic activities according to the Barthel Index; 2. instrumental activities according to the Lawton Index. Both indices assess dependence associated with the diagnosis of dementia, distinguishing it from the diagnosis of mild cognitive impairment.\n\nInclusion Criteria 'Mild Cognitive Impairment' group:\n\n* Diagnosis of mild cognitive impairment, based on a clinical and cognitive assessment conducted by a physician.\n* Preserved autonomy in: 1. basic activities according to the Barthel Index; 2. instrumental activities according to the Lawton Index. Both indices assess dependence associated with the diagnosis of dementia, distinguishing it from the diagnosis of mild cognitive impairment\n\nInclusion Criteria 'Subjective Cognitive Decline' group:\n\n* Adherence to SCD-I criteria.\n* Attendance at primary care consultation with memory complaints lasting more than 6 months.\n* Absence of a diagnosis of mild cognitive impairment or dementia.\n* Onset of subjective cognitive decline in the last 5 years.\n* Concerns related to subjective cognitive decline (not associated with an acute event) expressed by the participant and\u002For an informant.\n* Cognitive performance within the normal range on cognitive tests (MMSE (Mini Mental State Exam) \\\u003C 26 \u002F MIS (Memory Impairment Screen) \\\u003C 6).\n* No severe depressive symptoms, indicated by scores \\> 17\\* on the 30-item Geriatric Depression Scale.\n\nInclusion criteria No impairment group:\n\n* Cognitive performance within the normal range on cognitive tests (MMSE \\\u003C 26 \u002F MIS \\\u003C 6).\n* Absence of a diagnosis of mild cognitive impairment or dementia.\n* Not meeting the criteria for SCD-I \\[21\\].\n* Independent person living in their own home.\n* No subjective memory complaints.",{"count":295,"type":21},500,"3 Years","This study will investigate the validity of the HOGAR EEG\u002FPSG monitoring kit designed by Bitbrain as a tool for characterizing and assessing cognitive function in older adults, as well as for detecting and predicting cognitive decline. The kit consists of two EEG headbands and a mobile computing device that allows measurements of sleep patterns (PSG) and brain activity (EEG) in a home environment.",[203,29,299,300,27,301],"Dementia Alzheimers","Dementia, Mixed","Dementia, Vascular",[203,303,304,305,38,306],"MCI","Memory","cognitive decline","Sleep EEG","2025-05-19",{"date":309,"type":50},"2025-05-28",{"date":311,"type":50},"2024-01-15",{"date":313,"type":21},"2028-12-31",{"name":315,"class":316},"Bitbrain","INDUSTRY",{"id":318,"slug":4,"hasResults":11,"nctId":319,"briefTitle":320,"officialTitle":320,"acronym":4,"eligibilityCriteria":321,"healthyVolunteers":11,"sex":17,"minAge":119,"maxAge":4,"enrollmentInfo":322,"targetDuration":4,"studyType":22,"phases":323,"briefSummary":324,"conditions":325,"keywords":4,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":327,"lastUpdatePostDateStruct":328,"startDateStruct":330,"completionDateStruct":332,"leadSponsor":333,"locationsCount":58},"100543633","NCT06358404","Developing a Peer Support Intervention for Depression in SCD","Inclusion Criteria:\n\n* Older adults aged 60+\n* Endorse subjective cognitive decline\n* Endorse depressive symptoms\n* not currently experiencing suicidal ideation nor active, untreated manic, psychotic, or substance use disorder\n* fluent in English and able to give informed consent\n\nExclusion Criteria:\n\n* Meets diagnostic criteria for mild cognitive impairment or Alzheimer's dementia\n* Meets diagnostic criteria for a current major depressive disorder\n* have a history of neurological and psychiatric comorbidities such as major depressive disorder in the past 12 months",{"count":171,"type":21},[24],"The purpose of this study is to assess the feasibility, acceptability, and fidelity of an 8-week intervention where peer coaches will deliver depression care to adults 60 years of age or older who have depression and subjective cognitive decline.",[27,326],"Depression in Old Age","2025-05-09",{"date":329,"type":50},"2025-05-12",{"date":331,"type":50},"2024-05-01",{"date":109,"type":21},{"name":334,"class":57},"Massachusetts General Hospital",{"id":336,"slug":337,"hasResults":11,"nctId":338,"briefTitle":339,"officialTitle":340,"acronym":4,"eligibilityCriteria":341,"healthyVolunteers":11,"sex":17,"minAge":68,"maxAge":342,"enrollmentInfo":343,"targetDuration":4,"studyType":22,"phases":345,"briefSummary":346,"conditions":347,"keywords":348,"overallStatus":46,"whyStopped":4,"lastUpdateSubmitDate":355,"lastUpdatePostDateStruct":356,"startDateStruct":358,"completionDateStruct":360,"leadSponsor":362,"locationsCount":58},"100561344","phase-2--ohb-supplementation-and-brain-health-in-older-adults-100561344","NCT06588946","Β-OHB Supplementation and Brain Health in Older Adults","The Effect of Exogenous Β-OHB Supplementation on Cerebral Blood Flow and Functional Brain Characteristics in Adults with Subjective Cognitive Decline","Inclusion Criteria:\n\n* Being objectively cognitively normal as determined by a Montreal Cognitive Assessment (MoCA) score ≥26 with independent living and ambulating\n* SCD will be determined using the Prospective-Retrospective Memory Questionnaire (PRMQ) following the SCD Initiative Working Group framework\n\nExclusion Criteria:\n\n* A diagnosis of mild cognitive impairment, dementia, or psychiatric and\u002For mood disorders (e.g., major depression)\n* MoCA score \\\u003C26\n* Diagnosis of cardiometabolic disease (e.g., hypertension, type 2 diabetes)\n* Obesity (BMI \\>30 kg\u002Fm2)\n* History of heart attack or stroke\n* History of smoking\n* Currently following a ketogenic diet or taking ketogenic supplements\n* Having MRI contraindications\n* Participants with literacy, visual, hearing, and\u002For speech issues, as well as individuals who are not proficient in English will not be eligible for this trial","75 Years",{"count":344,"type":21},48,[196],"The goal of this randomized placebo controlled crossover trial is investigate the effects of short-term ketone monoester (KME) supplementation to brain function in older adults with subjective cognitive decline. We will test the hypothesis that KME supplementation will increase cerebral blood flow and improve resting-state functional connectivity in the brain compared to placebo supplementation in older adults with subjective cognitive decline.\n\nParticipants will be randomly assigned to either placebo of KME supplementation for 14 days. Following a washout period, participants will complete the alternate condition for 14 days. Outcome measures will be assessed before and after each intervention period.",[27],[349,350,351,352,353,354],"early-stage dementia","ketone monoester supplementation","cerebral blood flow","cognition","resting state functional magnetic resonance imaging","placebo","2025-02-24",{"date":357,"type":50},"2025-02-26",{"date":359,"type":21},"2025-03",{"date":361,"type":21},"2027-08",{"name":363,"class":57},"McMaster University",{"id":365,"slug":366,"hasResults":11,"nctId":367,"briefTitle":368,"officialTitle":368,"acronym":4,"eligibilityCriteria":369,"healthyVolunteers":67,"sex":17,"minAge":251,"maxAge":4,"enrollmentInfo":370,"targetDuration":372,"studyType":150,"phases":4,"briefSummary":373,"conditions":374,"keywords":4,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":377,"lastUpdatePostDateStruct":378,"startDateStruct":380,"completionDateStruct":382,"leadSponsor":384,"locationsCount":58},"100566114","china-diabetes-cognitive-dysfunction-early-diagnosis-and-intervention-study-china-decode-study-100566114","NCT06650969","China Diabetes Cognitive Dysfunction Early Diagnosis and Intervention Study (China-DECODE Study)","Inclusion Criteria:\n\n* Age ≥45 years;\n* Type 2 diabetes diagnosed according to the American Diabetes Association criteria;\n* Willingness and ability to complete systematic neuropsychological tests;\n* Understanding of the research procedures and methods, potential benefits and risks of the trial, and sign written informed consent.\n\nExclusion Criteria:\n\n* Fewer than 6 years of education;\n* Left-handedness;\n* Dementia;\n* Acute metabolic complications such as diabetic ketoacidosis, hyperglycaemic hyperosmolar state and hypoglycaemic coma within the previous 3 months;\n* History or presence of neurological or psychiatric disorders;\n* Presence of hypothyroidism;\n* History of malignancy, or severe kidney or liver dysfunction.",{"count":371,"type":21},10000,"10 Years","Type 2 diabetes (T2D) and dementia are both diseases with increasing incidence and prevalence globally, leading to substantial economic burdens for families and society. Notably, diabetes significantly increases the risk of cognitive dysfunction, which is classified into preclinical stage, mild cognitive impairment and dementia based on the disease severity. Cognitive dysfunction is a critical contributor to disability and mortality in elderly diabetes patients. Early diagnosis and intervention are crucial for delaying disease progression, enhancing treatment efficacy, and mitigating the impact of dementia. Currently, research and clinical management of cognitive dysfunction in individuals with diabetes are in their infancy, characterized by limitations such as single-center studies, limited sample sizes, inconsistent diagnostic criteria, and insufficient data sharing. Consequently, clinical diagnosis and treatment strategies are underdeveloped, medical staff's related knowledge is lacking, and potential therapeutic targets remain unexplored. In view of these problems and shortcomings, the population cohort study is supposed to be carried out based on accurate diagnosis and constructed the high standard information and sample bank. The study will establish the standard and quality system of T2D with cognitive dysfunction cohort study (unified standards and norms). The study will integrate the standard biological samples stratified acquisition function module (homogeneity and precision) of cognitive dysfunction in T2D, and complete the construction of biological samples bank and clinical diagnosis and treatment information database. The study will apply and develop brain structural and functional imaging technology to support precision diagnosis of cognitive dysfunction in T2D.",[375,27,29,203,376],"Type 2 Diabetes","Cognitive Dysfunction","2024-10-18",{"date":379,"type":50},"2024-10-21",{"date":381,"type":50},"2016-10-01",{"date":383,"type":21},"2034-10-01",{"name":385,"class":57},"The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School",{"id":387,"slug":388,"hasResults":11,"nctId":389,"briefTitle":390,"officialTitle":391,"acronym":392,"eligibilityCriteria":393,"healthyVolunteers":67,"sex":17,"minAge":68,"maxAge":394,"enrollmentInfo":395,"targetDuration":4,"studyType":22,"phases":397,"briefSummary":398,"conditions":399,"keywords":400,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":406,"lastUpdatePostDateStruct":407,"startDateStruct":409,"completionDateStruct":411,"leadSponsor":413,"locationsCount":58},"100549069","reducing-the-risk-of-cognitive-decline-ad-dementia-in-patients-with-subjective-cognitive-decline-through-an-immersive-virtual-reality-and-telemedicine-based-multi-component-intervention-the-scd-recoded-study-100549069","NCT06429215","REducing the Risk of COgnitive DEcline ad Dementia in Patients With Subjective Cognitive Decline Through an Immersive Virtual Reality and Telemedicine-based Multi-component Intervention: the SCD-ReCODED Study","Preventing Cognitive Decline and Dementia Through an Innovative Immersive Virtual Reality and Telemedicine-based Multi-component Intervention: a Randomized Controlled Trial","SCD-ReCODED","Inclusion Criteria:\n\n* Self-perceived decline in cognition compared to five years ago\n* Lack of objective cognitive impairment.\n\nExclusion Criteria:\n\n* Clinically significant depression and anxiety;\n* Psychiatric disorders;\n* Unstable medical conditions.\n* Severe visual, auditory, verbal or physical impairments interfere with communication, command compliance, and strategy execution\n* Dizziness or epilepsy history;","80 Years",{"count":396,"type":21},75,[24],"Older adults with subjective cognitive decline (SCD) are at high risk of developing dementia and frequently experience subclinical symptoms (e.g., anxiety, depression) which are themselves associated with dementia and cognitive decline risk. To date, the lack of effective disease-modifying treatments, along with the reliable identification of modifiable lifestyle risk factors (e.g., cognitive activity, dietary habits, physical exercise), have led to growing interest to invest in non-pharmacological interventions that may reduce the prevalence and incidence of dementia and cognitive decline in older adults. In this framework, the aim of this project is to evaluate the efficacy of an Immersive Virtual Reality (IVR) and telemedicine-based multi-component intervention, combining cognitive training and a health and lifestyle education program, for preventing cognitive decline and dementia in at-risk individuals (i.e., SCD). For this purpose, a randomized, double-blinded controlled trial (RCT) will be conducted on seventy-five eligible individuals with SCD, who will be randomly assigned to one of three conditions: (a) multi-component intervention (MC-I), including SCD-tailored cognitive IVR training plus a health and lifestyle education program, (b) cognitive-only intervention (CO-I), including the SCD-tailored cognitive IVR training plus an active control for the education program, and (c) active control intervention (AC-I) for both cognitive training and education program. Intervention will be provided in 20 at-home sessions (4 sessions\u002Fweek, each lasting about 30 minutes) over a period of 5 weeks. Outcome measures include clinical, neuropsychological, behavioural and neuroimaging data that will be collected before and immediately after intervention in order to detect potentially intervention-induced changes in objective cognitive functioning (primary outcome), subjective cognitive functioning, mood, quality of life and brain connectivity (secondary outcome). Users' compliance with IVR and telemedicine approach will be also evaluated, as well as individuals' factors affecting training efficacy.",[27],[401,402,403,404,405],"Subjective cognitive decline","Multi-component training","Non-pharmacological intervention","Virtual reality","Telemedicine","2024-09-30",{"date":408,"type":50},"2024-10-01",{"date":410,"type":50},"2024-07-01",{"date":412,"type":21},"2025-12",{"name":414,"class":57},"I.R.C.C.S. Fondazione Santa Lucia",{"id":416,"slug":417,"hasResults":11,"nctId":418,"briefTitle":419,"officialTitle":419,"acronym":4,"eligibilityCriteria":420,"healthyVolunteers":67,"sex":17,"minAge":91,"maxAge":421,"enrollmentInfo":422,"targetDuration":4,"studyType":150,"phases":4,"briefSummary":423,"conditions":424,"keywords":426,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":432,"lastUpdatePostDateStruct":433,"startDateStruct":435,"completionDateStruct":437,"leadSponsor":439,"locationsCount":58},"100559267","establish-diagnostic-and-prognostic-models-for-preclinical-ad-patients-based-on-multimodal-mri-behavioral-genetic-and-plasma-biomarkers-100559267","NCT06561906","Establish Diagnostic and Prognostic Models for Preclinical AD Patients Based on Multimodal MRI, Behavioral, Genetic, and Plasma Biomarkers","Inclusion Criteria:\n\n* The inclusion criteria were 50-79 years old and having 8 or more years of education.\n\nExclusion Criteria:\n\n* Participants with a history of stroke, other neurological disorders that could lead to cognitive impairment (Parkinson's disease, encephalitis, epilepsy, brain tumors, etc.), severe anxiety or depression, and contraindications for magnetic resonance imaging (MRI) were not enrolled.","79 Years",{"count":148,"type":21},"To establish the diagnostic and prognostic models that could help the preclinical identification of subjects at higher risk of clinical progression to mild cognitive impairment and dementia based on combined features of baseline demographic, cognitive, behavioral, multimodal MRI, genetic, and plasma data.",[425,29,27],"Alzheimer Disease, Late Onset",[427,428,429,430,431],"magnetic resonance imaging","spatial navigation","olfaction","genetic","plasma biomarkers","2024-08-16",{"date":434,"type":50},"2024-08-20",{"date":436,"type":50},"2020-09-01",{"date":438,"type":21},"2027-12",{"name":385,"class":57},{"id":441,"slug":442,"hasResults":11,"nctId":443,"briefTitle":444,"officialTitle":445,"acronym":4,"eligibilityCriteria":446,"healthyVolunteers":67,"sex":17,"minAge":447,"maxAge":448,"enrollmentInfo":449,"targetDuration":4,"studyType":150,"phases":4,"briefSummary":451,"conditions":452,"keywords":453,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":456,"lastUpdatePostDateStruct":457,"startDateStruct":459,"completionDateStruct":461,"leadSponsor":463,"locationsCount":58},"100557537","thinking-about-memory-how-confident-are-you-in-your-memory-and-does-it-change-with-age-100557537","NCT06539403","Thinking About Memory: How Confident Are You in Your Memory, and Does it Change With Age?","Thinking About Memory: How Confident Are You in Your Memory, and Does it Change With Age? Investigating Memory Ability and Confidence in Those Attending Memory Clinics.","Inclusion Criteria:\n\n* In age range given above\n* Referred to memory clinic\n* No other current psychiatric or neurological disorders, except for migraine\n* Can understand verbal or written information given in English.\n\nExclusion Criteria:\n\n* Outside age range given above\n* If they have a diagnosis of dementia and\u002For inability to provide informed consent.\n* Diagnosis of other neurological and\u002F or psychiatric problems.\n* Healthy participants will be excluded if they have participated in the previous study (King's REC ref: HR\u002FDP-21\u002F22-302230), as this study is a continuation of that.","65 Years","120 Years",{"count":450,"type":21},72,"Memory and our own beliefs and confidence in our ability to remember are important for our daily lives. For example, low confidence may hold us back from doing certain tasks, whereas misplaced high confidence in our memories may lead us to false beliefs about what has happened in the past.\n\nHowever, it is not fully understood how people form their beliefs about their memory abilities. These beliefs we hold about how good our memory is are form of evaluation of our own abilities known as 'metacognition'. The purpose of this study is to better understand how individuals, both with and without diagnosed memory difficulties, perform memory tasks and examine whether their metacognition of their memory performance depends on the type of memory task. That is, the study examines metacognition for different forms of memory; for example memory of our experienced life events as compared to memory for facts. There is still much more to learn about how individuals experience and think about their memories and memory abilities; and understanding this is important as some evidence suggests that good metacognition is associated with better outcomes after diagnosis of cognitive impairment. Understanding metacognitive beliefs about memory could be a route to earlier diagnosis and enable us to identify people who are likely to develop dementia.",[29,27],[304,454,29,27,455],"Metacognition","Ageing","2024-08-01",{"date":458,"type":50},"2024-08-06",{"date":460,"type":50},"2024-02-08",{"date":462,"type":21},"2025-06-30",{"name":464,"class":57},"King's College London",{"id":466,"slug":467,"hasResults":11,"nctId":468,"briefTitle":469,"officialTitle":469,"acronym":4,"eligibilityCriteria":470,"healthyVolunteers":67,"sex":17,"minAge":251,"maxAge":192,"enrollmentInfo":471,"targetDuration":149,"studyType":150,"phases":4,"briefSummary":473,"conditions":474,"keywords":4,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":478,"lastUpdatePostDateStruct":479,"startDateStruct":481,"completionDateStruct":483,"leadSponsor":485,"locationsCount":58},"100541897","the-effects-of-social-isolation-and-social-interaction-on-the-risk-of-dementia-progression-and-brain-function-in-scd-subjective-cognitive-decline-scd-100541897","NCT06335836","The Effects of Social Isolation and Social Interaction on the Risk of Dementia Progression and Brain Function in SCD (Subjective Cognitive Decline, SCD)","Inclusion Criteria:\n\n* SCD\n\n  1. Self-perceived continuous cognitive decline compared with the previous normal state, and is not related to acute events;\n  2. After adjustment for age, gender, and years of education, the standard cognitive test is normal, or the diagnostic criteria for MCI are not met;\n  3. Selected candidates can sign the informed consent form themselves.\n\nExclusion Criteria:\n\n* (a) Aged under 45 years or older than 85 years; (b) Vascular dementia or other central nervous system diseases; (c) Hachinski Ischemic Scale score \\> 4 points; (d); Unable to complete neuropsychological tests (e.g., blindness, deafness, severe language impairment); (e) Drug abuse or alcohol dependency within the last 6 months; (f) Current participation in other cognition studies; (g) Severe diabetes mellitus, or severe cardiovascular disease, cerebrovascular disease, liver diseases, kidney diseases, psychiatric disorders; (h) Contraindications to imaging techniques: claustrophobia, metallic implants (e.g., intracranial metal clips), electronic devices (e.g., cardiac pacemakers)",{"count":472,"type":21},209,"The goal of this clinical trial is to learn about the effects of social isolation and social interaction on the risk of dementia progression and brain function in SCD\n\n1. To explore the association between social isolation and lonely SCD populations and the occurrence and progression of MCI and AD through cross-sectional studies, cohort studies and randomized controlled trials of SCD;\n2. To clarify the correlation between different carrier states, resting brain function connectivity characteristics, and dual-task walking ability of APOEε4 allele and the progression of SCD to MCI and AD during the cognitive progress of people with SCD affected by social isolation;\n3. Establish a predictive model of cognitive decline from SCD to MCI and AD, and apply it to the SCD population to carry out individualized interventions;\n4. Confirm the protective effect of social interaction on cognitive level and brain function in SCD patients.",[475,476,27,303,29,477,28],"Social Isolation","SCD","AD","2024-03-21",{"date":480,"type":50},"2024-03-28",{"date":482,"type":50},"2024-03-01",{"date":484,"type":21},"2028-12-30",{"name":486,"class":57},"The First Affiliated Hospital with Nanjing Medical University"]